Yan Xie

List of Publications by Year
in descending order

48 papers	7,088 citations	136950 32 h-index	214800 47 g-index
54 all docs	54 docs citations	54 times ranked	7233 citing authors

#	Article	IF	Citations
1	Long-term cardiovascular outcomes of COVID-19. Nature Medicine, 2022, 28, 583-590.	30.7	1,029
2	Risks of mental health outcomes in people with covid-19: cohort study. BMJ, The, 2022, 376, e068993.	6.0	199
3	Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 311-321.	11.4	289
4	Long COVID after breakthrough SARS-CoV-2 infection. Nature Medicine, 2022, 28, 1461-1467.	30.7	460
5	Acute Kidney Injury in a National Cohort of Hospitalized US Veterans with COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 14-25.	4.5	158
6	Development and validation of lupus nephritis case definitions using United States veterans affairs electronic health records. Lupus, 2021, 30, 518-526.	1.6	4
7	Temporal Trends in Incidence Rates of Lower Extremity Amputation and Associated Risk Factors Among Patients Using Veterans Health Administration Services From 2008 to 2018. JAMA Network Open, 2021, 4, e2033953.	5.9	53
8	County-Level Contextual Characteristics and Disparities in Life Expectancy. Mayo Clinic Proceedings, 2021, 96, 92-104.	3.0	11
9	Ambient Fine Particulate Matter Air Pollution and Risk of Weight Gain and Obesity in United States Veterans: An Observational Cohort Study. Environmental Health Perspectives, 2021, 129, 47003.	6.0	32
10	High-dimensional characterization of post-acute sequelae of COVID-19. Nature, 2021, 594, 259-264.	27.8	961
11	Clinical Implications of Estimated Glomerular Filtration Rate Dip Following Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Initiation on Cardiovascular and Kidney Outcomes. Journal of the American Heart Association, 2021, 10, e020237.	3.7	19
12	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetes. JAMA Internal Medicine, 2021, 181, 1043.	5.1	32
13	Temporal trends of COVID-19 mortality and hospitalisation rates: an observational cohort study from the US Department of Veterans Affairs. BMJ Open, 2021, 11, e047369.	1.9	29
14	Kidney Outcomes in Long COVID. Journal of the American Society of Nephrology: JASN, 2021, 32, 2851-2862.	6.1	200
15	Ambient fine particulate matter air pollution and the risk of hospitalization among COVID-19 positive individuals: Cohort study. Environment International, 2021, 154, 106564.	10.0	70
16	Comparative Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors vs Sulfonylureas in Patients With Type 2 Diabetesâ€"Reply. JAMA Internal Medicine, 2021, , .	5.1	0
17	Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nature Communications, 2021, 12, 6571.	12.8	196
18	Proton Pump Inhibitors and the Kidney: Implications of Current Evidence for Clinical Practice and When and How to Deprescribe. American Journal of Kidney Diseases, 2020, 75, 497-507.	1.9	86

#	Article	IF	Citations
19	Comparative Effectiveness of SGLT2 Inhibitors, GLP-1 Receptor Agonists, DPP-4 Inhibitors, and Sulfonylureas on Risk of Kidney Outcomes: Emulation of a Target Trial Using Health Care Databases. Diabetes Care, 2020, 43, 2859-2869.	8.6	68
20	Comparative Effectiveness of the Sodiumâ€"Glucose Cotransporter 2 Inhibitor Empagliflozin Versus Other Antihyperglycemics on Risk of Major Adverse Kidney Events. Diabetes Care, 2020, 43, 2785-2795.	8.6	26
21	Comparative evaluation of clinical manifestations and risk of death in patients admitted to hospital with covid-19 and seasonal influenza: cohort study. BMJ, The, 2020, 371, m4677.	6.0	129
22	Diabetes Minimally Mediated the Association Between PM2.5 Air Pollution and Kidney Outcomes. Scientific Reports, 2020, 10, 4586.	3.3	21
23	The global and national burden of chronic kidney disease attributable to ambient fine particulate matter air pollution: a modelling study. BMJ Global Health, 2020, 5, e002063.	4.7	40
24	Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ: British Medical Journal, 2019, 365, l1580.	2.3	146
25	Estimates of the 2016 global burden of kidney disease attributable to ambient fine particulate matter air pollution. BMJ Open, 2019, 9, e022450.	1.9	58
26	Burden of Cause-Specific Mortality Associated With PM_{2.5} Air Pollution in the United States. JAMA Network Open, 2019, 2, e1915834.	5.9	205
27	The association of proton pump inhibitors and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 182-187.	2.0	16
28	Particulate Matter Air Pollution and the Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2018, 29, 218-230.	6.1	225
29	Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney International, 2018, 93, 741-752.	5.2	104
30	Changes in the US Burden of Chronic Kidney Disease From 2002 to 2016. JAMA Network Open, 2018, 1, e184412.	5.9	106
31	The 2016 global and national burden of diabetes mellitus attributable to PM 2Â·5 air pollution. Lancet Planetary Health, The, 2018, 2, e301-e312.	11.4	240
32	Analysis of the Global Burden of Disease study highlights the global, regional, and national trendsÂof chronic kidney disease epidemiology from 1990 to 2016. Kidney International, 2018, 94, 567-581.	5.2	592
33	Blood urea nitrogen and risk of insulin use among people with diabetes. Diabetes and Vascular Disease Research, 2018, 15, 409-416.	2.0	15
34	Monocyte count modifies the association between chronic kidney disease and risk ofÂdeath. Clinical Nephrology, 2018, 90, 194-208.	0.7	5
35	Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International, 2017, 91, 1482-1494.	5.2	134
36	Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 603-613.	4.5	56

#	Article	IF	Citations
37	Associations of ambient coarse particulate matter, nitrogen dioxide, and carbon monoxide with the risk of kidney disease: a cohort study. Lancet Planetary Health, The, 2017, 1, e267-e276.	11.4	131
38	The Authors Reply. Kidney International, 2017, 92, 515-516.	5.2	2
39	Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open, 2017, 7, e015735.	1.9	194
40	Geographic Variation and US County Characteristics Associated With Rapid Kidney Function Decline. Kidney International Reports, 2017, 2, 5-17.	0.8	42
41	Serum phosphorus levels and risk of incident dementia. PLoS ONE, 2017, 12, e0171377.	2.5	25
42	Renal Function Trajectories in Patients with Prior Improved eGFR Slopes and Risk of Death. PLoS ONE, 2016, 11, e0149283.	2.5	29
43	Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3153-3163.	6.1	263
44	High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1784-1793.	4.5	157
45	A prognostic scoring system for arm exercise stress testing. Open Heart, 2016, 3, e000333.	2.3	2
46	Low levels of high-density lipoprotein cholesterol increase the risk of incident kidney disease and its progression. Kidney International, 2016, 89, 886-896.	5.2	101
47	Estimated GFR Trajectories of People Entering CKD Stage 4 and Subsequent Kidney Disease Outcomes and Mortality. American Journal of Kidney Diseases, 2016, 68, 219-228.	1.9	45
48	Rate of Kidney Function Decline and Risk of Hospitalizations in Stage 3A CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1946-1955.	4.5	51